Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.06Palanor: Geopolitical Stress59.7-0.25Palanor: Liquidity58.8+0.87Palanor: Capital Tightness46.4-1.11Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression52.8-0.63Palanor: Consumer Confidence47.1-1.44Palanor: US Dollar Strength46.5+0.01Palanor: Labor Heat63.20.00Palanor: Recession Vocabulary28.7+0.64Palanor: Uncertainty Index53.2-0.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.7+0.74Palanor: Reshoring Sentiment22.7-0.15Palanor: AI Substitution28.6+0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.8+0.43Palanor: Quit Pressure34.7-2.85The Mania Index88.00.00The Palanor Index57.5+0.37Cost Disease Spread33.20.00Palanor: US vs China49.4-0.05Rise of Socialism Index40.6-0.18The Bubble Memory98.5-0.00Palanor: Steward Confidence51.0+0.19The Long Watch90.30.00The Reshoring Index55.20.00The Capital Return Index80.2-0.77The Discourse Index74.3+1.91The Hesitation Index33.4+2.64Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index76.1-2.39The Boardroom Index81.7-0.84The Layoff Cycle Index35.6+2.75Capital Deployment Posture Index61.7-0.67The Consumer Health Index41.8+0.07Labor Hours Composite44.40.00The Dollar Erosion Index65.5-1.13Palanor: Risk Appetite35.4-0.76
PalanorPalanor
Terminal News·Council··1 min read

TRex Bio raises $117M in IPO priced at $14

The immunology drug developer backed by Eli Lilly priced shares at $14 and closed flat on its trading debut.

image · feed

Palanor Wire · composed from 3 outlets · every claim links to its sources

What happened

The company raised $117 million in the IPO. 23 Shares closed flat at the IPO price on their trading debut. 1 Eli Lilly is the largest equity holder in TRex Bio. 23 TRex Bio is developing drugs that treat immunological conditions by activating Treg cells. 2

Why it matters

Treg cells are a specialized type of regulatory T cell that modulates immune responses. 2 The deal indicates continued investor appetite for biotech IPOs backed by large pharmaceutical companies. 3

Sources · 3

  • [1]TRex Bio prices $117M IPO to support immune drug work

    BioPharma Dive

    Read at source →

  • [2]TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension

    Endpoints News

    Read at source →

  • [3]Eli Lilly-backed TRex Bio closes day flat after IPO (TRXB:NASDAQ)

    seekingalpha.com · via Marketaux

    Read at source →

Matched signals

Lattice signals Numen pinned to this story at publish time.

Member +

No matched signals on this story.

Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.

Upgrade →

On X right now

Top engagement posts about this topic, ranked by likes + retweets + quotes.

Member +

No high-engagement X posts captured for this topic. Either the topic is too quiet or the upstream API was unavailable when this article published.

Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.

Upgrade →

Your read

How did this article land?

Three sliders. Optional comment. Anonymous is fine.

Accuracy50
Got it wrongGot it right
Bias50
Skews leftSkews right
Importance50
NoiseMatters

Open to anyone. One response per reader.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.